e-Therapeutics plc Directorate Change (0166X)
February 16 2017 - 1:00AM
UK Regulatory
TIDMETX
RNS Number : 0166X
e-Therapeutics plc
16 February 2017
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Directorate Change
Oxford, UK, 16 February 2017 - e-Therapeutics plc (AIM:ETX)
announced today that Sean Nicolson, Executive Director &
Company Secretary will be leaving in order to focus on other
business commitments.
Iain Ross, Chairman said:
"Over the last year this business has gone through a period of
transition culminating with the recent announcement of the
appointment of Dr. Raymond Barlow as our new CEO. During this
period Sean has made a significant contribution and will leave the
Company on 28 February. I would like to thank him personally for
his support and to wish him every success in the future."
-Ends-
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993 883 125
Iain Ross, Chairman www.etherapeutics.co.uk
Steve Medlicott, Finance Director
Numis Securities Limited Tel: +44 (0) 207 260 1000
Michael Meade / Freddie Barnfield (Corporate www.numis.com
Finance)
James Black (Corporate Broking)
Instinctif Partners Tel: +44 (0) 207 457 2020
Melanie Toyne-Sewell / Alex Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a
proprietary discovery platform based on advances in network
pharmacology and chemical biology. The Company is applying its
platform to the discovery of new drug candidates. The therapeutic
focus of the Company's activity is in immuno-oncology, addressing
drug resistance in targeted cancer therapies and anti-infectives.
The platform is highly productive, yielding multiple potent and
selective molecules at a much higher rate and more quickly than is
reported for conventional drug discovery.
e-Therapeutics has a variety of preclinical stage assets,
ETS2300, telomerase inhibition in anti-cancer; ETS3100, small
molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway
inhibition; ETS5200, broad spectrum antivirals together with two
immuno-oncology checkpoint projects.
The Company is fully funded to advance its drug discovery
programmes. It is based in Oxford, UK. For more information, visit
www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABIGDDLSBBGRU
(END) Dow Jones Newswires
February 16, 2017 02:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024